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Purpose of the study
Monotherapy maintenance with 3TC after multiple thera-
peutic failure, helps in maintaining the number of CD4,
but, at the same time, slows down the speed of reversion
of mutations usually achieved during complete interrup-
tion of therapy. Monotherapy with enfuvirtide (T20) can
be an interesting alternative to 3TC monotherapy, due to
the CD4-enhancement typical of this drug even during
therapeutic failure. Aim of this study was to assess, in a
proof-of-concept study, the efficacy of T20-monotherapy
to maintain the levels of CD4, to allow reversal of muta-
tions in the pol gene, and eventually to favor long-term
success of subsequent HAART.
Methods
In a pilot study named Reverfuzeon, four multi-failed
HIV-infected patients with detectable viral load, nadir of
CD4 <200/mmc, low compliance to a complex and long-
term treatment and with 0–1 fully active drug, were
enrolled from 2004 to the beginning of 2006. All patients
were on ARV for more than 10 years and all were exposed
to NRTI, NNRTI and PI. Authors decided to establish a
T20-monotherapy for a mean time of 180 days (range:
151–203) to achieve the reversion of all mutations
expressed in pol gene maintaining an antiretroviral activ-
ity. Afterward patients started a new regimen containing
TDF+FTC+TPV/r.
Summary of results
The mean CD4+ value before starting the T20-mono-
therapy was 308/mmc (190–554) and at the end was 241/
mmc (187–307), with a variation of CD4+ value of only
66/mmc in a 180 days average. Viral load did not show
relevant deviations from a mean baseline value of 72,740
cps/ml (range: 2,500–270,000). Mutations during T20-
monotherapy decreased substantially for NRTI, NNRTI
and PI from 5 (range: 4–7), 1.75 (0–3), 12.5 (9–14),
respectively, to 1.25 (0–4), 0.25 (0–1), 4.75 (1–9) after
the end of T20-monotherapy assumption. Successively,
after 12 months from starting the regimen containing
TDF+FTC+TPV/r, plasma HIV-RNA was undetectable with
an increase of 100/mmc CD4+. In three patients followed
for ≥24 months (min 24, max 40 months) the viral load
was still undetectable and a further increase of CD4+ was
observed.
Conclusion
In this pilot study it was possible to build up an effective
treatment where no other options were active at the
moment of the study design, by reducing the number of
resistance mutations. The T20-monotherapy resulted in a
well tolerated treatment, from which to restart to obtain a
virological success in multi-failed patients.
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